IRLAB Publishes Interim Report for the Period January – September 2024
GOTHENBURG, SWEDEN / ACCESSWIRE / October 30, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company...
Brain
3X4 Genetics and Fullscript Announce next step in Partnership to Enhance Whole Person Care Through Genetic Insights
BELLEVUE, Wash., Oct. 29, 2024 /PRNewswire/ -- 3X4 Genetics, a pioneer in functional nutrigenomics, is thrilled to announce the next step...
QuantalX Introduces a Breakthrough in the Diagnosis and Classification of Parkinson’s Disease
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- QuantalX Neuroscience, a leader in objective neurodiagnostic technology, announces a significant discovery in the...
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase...
BrainsWay to Report Third Quarter 2024 Financial Results On November 12, 2024
BURLINGTON, Mass. and JERUSALEM, Oct. 29, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development
CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, a clinical-stage biotechnology company focused on re-engineering drug development through artificial...
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA)...
Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
Company will present results from the ReSPECT-LM Phase 1 clinical trial of Rhenium (186Re) Obisbemeda for leptomeningeal metastases (LM) and...
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel...
Neumora Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
WATERTOWN, Mass., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics...
Linus Health to Demonstrate How Digital Health Powers Innovation at Clinical Trials on Alzheimer’s Disease (CTAD)
Leaders to deliver four poster presentations showing how its digital health platform lowers investigator burden, enables precision recruitment, and delivers...
The Tianqiao & Chrissy Chen Institute’s OMNE Framework for Long-term AI Memory Claims Top Spot on GAIA Leaderboard
REDWOOD CITY, Calif., Oct. 28, 2024 /PRNewswire/ -- Drawing on their deep knowledge of the brain and memory, the Tianqiao...
IRLAB Reports Continued Progress Ahead of the Mesdopetam Phase III Program
GOTHENBURG, SWEDEN / ACCESSWIRE / October 29, 2024 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company...
Alimetry revolutionises gut health diagnosis by integrating AI into its wearable device, raises US $18m to fuel next phase of growth
MINNEAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Alimetry has raised an oversubscribed US $18m A2 financing round to commercialise its wearable gut...
Fountain Life Develops “Zora AI,” the World’s First Generative AI Platform Specially Trained in Functional and Longevity Medicine
LAKE NONA, Fla., Oct. 28, 2024 /PRNewswire/ -- Fountain Life, a company that offers longevity, preventative health, advanced diagnostics, and...
IRLAB: Invitation to the Interim Report for Q3 2024 Presentation and Webcast
GOTHENBURG, SWEDEN / ACCESSWIRE / October 28, 2024 / IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing...
Nexalin Technology Announces Landmark Study on Alzheimer’s Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer’s Disease
New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients HOUSTON, TX, Oct. 28, 2024 (GLOBE...
AlzeCure Presents New Positive Data for the TrkA-NAM Pain Project Against Osteoarthritis
STOCKHOLM, SE / ACCESSWIRE / October 28, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)...
Neuromorphic Computing Market worth $1,325.2 million by 2030 – Exclusive Report by MarketsandMarkets™
DELRAY BEACH, Fla., Oct. 25, 2024 /PRNewswire/ -- The neuromorphic computing market is expected to grow from USD 28.5 million in 2024...